



FOR IMMEDIATE RELEASE

CONTACT

Michaella Videka, Marketing Coordinator, HOPA
847-375-4849 | mvideka@hoparx.org

HOPA Announces the 2019 Class of Fellow of the Hematology/Oncology Pharmacy Association

Chicago, IL (April 4, 2019): The Hematology/Oncology Pharmacy Association (HOPA) is pleased to announce the 2019 class of Fellow of the Hematology/Oncology Pharmacy Association (FHOPA). This designation recognizes individuals who have made sustained contributions to HOPA and who also have demonstrated exceptional performance in oncology pharmacy. The 2019 class of HOPA Fellows are:

Val Adams, PharmD BCOP FCCP FHOPA is an Associate Professor in the department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. He co-chairs the protocol review and monitoring committee for the NCI Designated Markey Cancer center. As the director of the hematology / oncology residency program, he has trained forty PGY2 oncology residents and maintains an active research program. He has trained two post-doctoral fellows, been the thesis advisor for 4 masters students, and served on 20 PhD dissertation student committees and was advisor or co-advisor for 7 of them. He received his B.S. in pharmacy from the University of Utah and received his doctor of pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology / oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship he joined the University of Kentucky faculty in 1996.

David L. DeRemer, PharmD, is a Clinical Associate Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida (UF) College of Pharmacy. He currently serves as the Assistant Director of the Experimental Therapeutics Incubator at the UF Health Cancer Center. Dr. DeRemer obtained his BS and PharmD degrees from the University of Kentucky (UK). He also completed his PGY-1, PGY-2 Oncology residency, and an oncology fellowship from UK. Dr. DeRemer is a past HOPA At-Large Board Member and has been active in HOPA for ten years serving on several committees and task forces. His teaching, clinical service, and scholarship interests include biomarker assessment in novel therapeutic clinical trials, cancer genomics, and supportive care in oncology patients.

Patrick Kiel, PharmD BCPS BCOP FHOPA, is a clinical pharmacy specialist at Indiana University (IU) Simon Cancer Center in Indianapolis, Indiana. He received his Doctor of Pharmacy degree from Midwestern University Chicago College of Pharmacy. Dr. Kiel completed his PGY1 residency at Rush University Medical Center and his PGY2 specialty residency in hematology/oncology at Indiana University Hospital. He has



provided clinical services for the Hematology and Hematopoietic Cell Transplant programs and is currently part of the Precision Genomic Program at the IU Simon Cancer Center. Dr. Kiel has been a director of the IU Health Oncology PGY2 Residency. He holds academic appointments at the IU School of Medicine and Purdue University School of Pharmacy. He is published in peer-reviewed journals, and his research interests include genomically guided therapy in patients with refractory metastatic cancer and novel targeted therapies. Dr. Kiel enthusiastically supports the mission of HOPA with a focus on promoting pharmacist-led research and direct patient care. He has been active for several years on the Research Committee and the Basic and Translational Science Committee.

Jill Rhodes, PharmD BCOP CSP, is a Pharmacy Specialist at the University of Louisville Hospital (ULH) and COO for St. Matthews Community / Specialty Pharmacy in Louisville, Kentucky. She completed residency training at the University of Kentucky Chandler Medical Center. Dr. Rhodes is the PGY2 ULH Oncology Pharmacy Residency Program founding director and has precepted over 20 PGY1 / PGY2 residents and 40 students.

Dr. Rhodes is an active HOPA volunteer recently appointed to the Kentucky Board of Pharmacy. She has served as a HOPA Board Director and volunteer for Program, BCOP Oversight and Patient Outreach Committees. She is an advocate for pharmacy practice advancement and patient access to services. Dr. Rhodes has testified before the Kentucky Senate supporting legislation that improved oral cancer drug parity. She helped revise the Kentucky statute defining pharmacy collaborative care agreement to expand pharmacy access. She provides pharmacy services in the community, including the implementation of a pharmacist-led board approved protocol for medication assisted treatment of opioid use disorder. She is a Girl Scouts of America volunteer and blessed mother of three children.

Rowena N. Schwartz, PharmD BCOP FHOPA, is an oncology pharmacist and faculty member at the University of Cincinnati College of Pharmacy, with a clinical practice at the Barrett Cancer Center in ambulatory oncology and Phase I clinical trials.

Dr. Schwartz received a Bachelor of Science at the University of Illinois and her Doctor of Pharmacy at the University of Texas. She completed a fellowship in oncology drug development at the University of Texas.

Dr. Schwartz started her career at the University of Pittsburgh and the Pittsburgh Cancer Institute. She served as Director of Oncology Pharmacy Services at Johns Hopkins Hospital and maintained a clinical practice at the Sidney Kimmel Cancer Center. Dr. Schwartz worked with The US Oncology Network as Vice President of Clinical Content and Pharmacy Operations at McKesson Specialty Health.

Dr. Schwartz has taught at schools of pharmacy including the University of Pittsburgh, Duquesne University, University of Maryland, Charleston College of Pharmacy and Misr International University in Cairo, Egypt. She is an active member of oncology and pharmacy organizations including HOPA, ASHP, ASCO, ONS and ISOPP.

Judith A. Smith, PharmD BCOP CPHQ FCCP FISOPP FHOPA, is an Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UTHealth McGovern Medical School and Director of



the Women's Health Integrative Medicine Research Program. She also is an oncology clinical pharmacy specialist at the UTHealth-Memorial Hermann Cancer Center. She received a Bachelor of Science in Pharmacy and Doctor of Pharmacy from Union University Albany College of Pharmacy. She completed residency in Pharmacy Practice and Oncology Pharmacy Practice at NIH followed by a fellowship in Clinical Pharmacology at UT M.D. Anderson Cancer Center(UTMDACC). Previously she was a Faculty member in the Department of Gynecologic Oncology at UTMDACC. Dr. Smith is an active member of many pharmacy professional organizations. She has been Board Certified in Oncology Pharmacy and Certified Professional in Healthcare Quality. Her research mission is to advance the progress of the safe and effective use of nutritional and herbal supplements with pharmacologic modalities as it relates to women's health and cancer through innovative thinking, systematic methodology and collaborative interactions throughout the UTHealth System and global research community.

Scott Soefje, PharmD MBA BCOP FCCP FHOPA, is the Director of Pharmacy Cancer Care Services at the Mayo Clinic in Rochester, MN.

He earned his Bachelor's Degree in Pharmacy from The University of Texas at Austin and then after almost five years of hospital practice, he returned to earn a PharmD from the joint program at The University of Texas at Austin and The University of Texas Health Sciences Center at San Antonio. He stayed in San Antonio to complete an ASHP accredited specialty residency in oncology from the Audie L. Murphy Veterans Hospital followed by a Clinical Pharmacology Fellowship from the U.T. M.D. Anderson Cancer Center in Houston. He obtained an MBA focusing on healthcare from The George Washington University in 2012. He has been board certified in oncology pharmacy since 2000. He is a Fellow of the American College of Clinical Pharmacy. He has served on the HOPA board, many different HOPA committees and task forces, and is a past president of HOPA.

Steve Stricker, PharmD MS BCOP FHOPA, currently serves as a Senior Medical Science Liaison and Associate Director of US Medical Affairs for Takeda Oncology. After finishing his doctor of pharmacy degree at the University of Missouri - Kansas City, he completed his PGY-1 pharmacy residency at the University of North Carolina and a PGY-2 hematology/oncology pharmacy residency at Emory Healthcare in Atlanta, Georgia. Dr. Stricker has held numerous leadership and advisory positions within the Hematology/Oncology Pharmacy Association (HOPA), the International Society of Oncology Pharmacy Practitioners (ISOPP), American Society of Blood and Marrow Transplantation (ASBMT) and other professional pharmacy organizations. He has been an invited speaker, lecturer, and visiting faculty member for conferences, workshops and schools of pharmacy throughout North and South America, Europe, Asia and Australia. Additionally, Dr. Stricker has authored more than 75 manuscripts, invited editorials and textbook chapters and has been the recipient of several clinical practice and teaching awards including the 2013 HOPA New Practitioner Award and was recently recognized as a 2018 Fellow of the International Society of Oncology Pharmacy Practitioners.

About HOPA

Hematology/Oncology Pharmacy Association (HOPA) is a nonprofit, education-based organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates the best possible cancer care. HOPA supports research, provides education, encourages professional development and advocates for health policy issues



that improve patient care. HOPA serves more than 2,700 members in the fields of oncology pharmacy, pharmacy administration, and research, and includes pharmacy residents, interns, and technicians specializing in hematology/oncology practice.